Écrit par Pluristem | 03 Avril 2012

A Team of Internationally Renowned Physicians Will Collaborate on Advancing PLX Cell Therapies for Millions of People Suffering from the Chronic Disease



HAIFA, ISRAEL, April 3, 2012 -- Pluristem Therapeutics, Inc. (NASDAQ:PSTI; TASE: PLTR) today announced that it has formed a steering committee to assist in advancing PLacental eXpanded (PLX) cell therapies for the treatment of...

Écrit par JS Bio | 29 Mars 2012

N°1 dans le Var, N°2 dans le Vaucluse et N°3 dans les Bouches-du-Rhône en nombre de laboratoires, JS BIO s’est hissé en 2 ans au rang de leader des acteurs de la biologie médicale en PACA. Cette structure fédérative de biologistes réunira 44 laboratoires fin mars et s’impose d’ores et déjà comme un acteur de la santé emblématique en matière de qualité et de niveau de...

Écrit par Pluristem Therapeutics | 20 Mars 2012

Significantly improved cardiac function, smaller infarct size with greater regional left ventricle wall thickness and the pronounced stimulation of new vessels formation were observed in animals treated with PLX cells



HAIFA, ISRAEL, March 20, 2012 -- Pluristem Therapeutics, Inc. (NASDAQ:PSTI; TASE: PLTR) today announced that its PLacental eXpanded (PLX) cells, tested in a preclinical...

Écrit par Pluristem | 12 Mars 2012

Scale up of bioreactors to allow production of about 30 billion cells with each reactor run

HAIFA, ISRAEL, March 12, 2012 -- Pluristem Therapeutics, Inc. (NASDAQ:PSTI; TASE: PLTR) today announced that it has initiated the process of scaling up the Company’s manufacturing bioreactors from their current size of 5 liter (L) to 15L. The up scaling process is being coordinated to go on-line...